

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**(1) POLL RESULTS OF  
THE ANNUAL GENERAL MEETING HELD ON JUNE 6, 2025;  
(2) CHANGE OF DIRECTOR; AND  
(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board announces that:

- (1) at the AGM held on June 6, 2025, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll;
- (2) Dr. Weichang Zhou retired as a non-executive Director and a member of the Strategy Committee with effect from the conclusion of the AGM;
- (3) Dr. Sherry Xuejun Gu was appointed as an executive Director and a member of the Strategy Committee with effect from the conclusion of the AGM; and
- (4) Dr. Jue Chen was appointed as a member of the Nomination Committee with effect from June 6, 2025.

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 6, 2025

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司\* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 6, 2025, all proposed resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 15, 2025 (the “**Circular**”). Dr. Zhisheng Chen, Dr. Sherry Xuejun Gu, Dr. Ge Li, Mr. William Robert Keller and Mr. Jackson Peter Tai attended the AGM either in person or by electronic means.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and of the independent auditor of the Company for the year ended December 31, 2024.	1,935,940,685 (99.69%)	6,009,248 (0.31%)
2.	To re-elect and appoint the following Directors, each as a separate resolution:		
	(a) To re-elect Dr. Zhisheng Chen as executive Director.	1,918,866,090 (98.81%)	23,083,843 (1.19%)
	(b) To re-elect Mr. Yanling Cao as non-executive Director.	1,772,804,361 (91.29%)	169,145,572 (8.71%)
	(c) To re-elect Ms. Jingwen Miao as non-executive Director.	1,829,984,153 (94.23%)	111,965,780 (5.77%)
	(d) To re-elect Mr. Jackson Peter Tai as independent non-executive Director.	1,835,809,441 (94.53%)	106,140,492 (5.47%)
	(e) To appoint Dr. Sherry Xuejun Gu as executive Director.	1,921,683,869 (98.96%)	20,266,064 (1.04%)
3.	To authorize the Board or any duly authorized board committee to fix the Directors’ remuneration for the year ending December 31, 2025.	1,941,683,206 (99.99%)	266,727 (0.01%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the Board or any duly authorized board committee to fix their remuneration.	1,917,528,958 (98.74%)	24,420,975 (1.26%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company (including any sale or transfer of treasury shares).	1,877,834,573 (96.70%)	64,115,360 (3.30%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	1,941,873,433 (99.996%)	76,500 (0.004%)

*Notes:*

- (1) As at the date of the AGM, (i) the total number of Shares in issue was 4,068,680,773; and (ii) there were no treasury Shares held by the Company.

Accordingly, the total number of Shares entitling the holders thereof to attend and vote on all the resolutions proposed at the AGM is 4,068,680,773.

- (2) There were no Shares entitling the holders thereof to attend and abstain from voting in favour of any resolution at the AGM as set out in Rule 13.40 of the Listing Rules.
- (3) As at the date of the AGM, Computershare Hong Kong Trustees Limited, being the trustee (the “**Trustee**”) holding unvested Restricted Shares granted under the Restricted Share Award Scheme and/ or the Global Partner Program Share Scheme, held 54,113,750 Shares.

Save for the Trustee who was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders’ approval under the Listing Rules, no other Shareholder was required to abstain from voting in respect of any resolution at the AGM.

- (4) The Company’s Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

## CHANGE OF DIRECTOR

Dr. Weichang Zhou retired as a non-executive Director and a member of the Strategy Committee with effect from the conclusion of the AGM to devote more time to his own personal commitments. Dr. Zhou has confirmed that he has no disagreement with the Board, and there are no matters relating to his retirement that need to be brought to the attention of the Shareholders or the Stock Exchange. The Board would like to express their sincere gratitude to Dr. Zhou for his dedication during his tenure of service over the past 12 years.

The Board is also pleased to announce that Dr. Sherry Xuejun Gu has been appointed as an executive Director with effect from the conclusion of the AGM. The biographical details of Dr. Gu are as follows:

Dr. Sherry Xuejun Gu, aged 54, is the Chief Technology Officer and Executive Vice President of the Company. She joined the Company in 2017 as the Vice President of CMC (Chemistry, Manufacturing and Controls) Management for the West Coast of the United States, and expanded her responsibilities to include the East Coast of the United States in 2019 and Europe in 2021. During such period, she led numerous early and late-stage CMC projects directly and achieved several project IND (Investigational New Drug), PPQ (Process Performance Qualification) and approval milestones, including from DNA to EUA (Emergency Use Authorization) approval of Sotrovimab through the VIR-GSK collaboration in the combat of the worldwide COVID-19 pandemic. Dr. Gu received her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and has been working in the biopharmaceutical field for over 28 years, including two years at Bristol Myers Squibb and 18 years at Eli Lilly and Company prior to joining the Company.

Dr. Gu does not, at present, nor did she in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas.

Dr. Gu has entered into a director's service agreement with the Company for a term of three years which is terminable by either party with three months' written notice, and she is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provisions of the articles of association of the Company. Dr. Gu does not have any relationships with any Directors or senior management or substantial Shareholders or controlling Shareholders of the Company.

As at the date of this announcement, Dr. Gu was deemed to be interested in 1,247,470 Shares, 1,043,582 Restricted Shares granted to her under the Restricted Share Award Scheme and 94,381 Restricted Shares granted to her under the Global Partner Program Share Scheme, which entitling her to receive a total of 1,137,963 Shares upon vesting within the meaning of Part XV of the SFO. Dr. Gu also directly held 114,500 shares of WuXi XDC, an associated corporation of the Company within the meaning of Part XV of the SFO.

Dr. Gu is entitled to a chief technology officer and executive vice president's salary of US\$400,000 per annum and a discretionary bonus, which is determined by the Board at the recommendation of the Remuneration Committee with reference to the Company's performance, the prevailing market condition and her performance. Dr. Gu is not entitled to any director's fee for her services as an executive Director.

There is no information which is discloseable nor is/was Dr. Gu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to Dr. Gu's election that need to be brought to the attention of the Shareholders.

The Board would like to extend its warmest welcome to Dr. Gu on her new appointment.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

Dr. Weichang Zhou retired as a non-executive Director and a member of the Strategy Committee with effect from the conclusion of the AGM on June 6, 2025. The Board further announces that Dr. Sherry Xuejun Gu was appointed as a member of the Strategy Committee and Dr. Jue Chen was appointed as a member of the Nomination Committee, all with effect from June 6, 2025.

For and on behalf of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, June 6, 2025

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu as executive Directors; Dr. Ge Li, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

\* *For identification purpose only*